Thesis icon

Thesis

Herceptin resistance in HER2-moderately expressed breast cancer

Abstract:

HER2 overexpression occurs in approximately 15-20% of all breast cancers and is associated with poor prognosis. The development of Herceptin, a monoclonal antibody against HER2, has been significant in prolonging survival of these patients. Herceptin is less efficient in patients who do not overexpress HER2, so-called HER2-negative, such that they are not eligible for treatment with this drug. An incomplete understanding of Herceptin action and HER2 classification means that the...

Expand abstract

Actions


Access Document


Files:

Authors


More by this author
Institution:
University of Oxford
Research group:
Human EGFR
Department:
Medical Sciences Division - Medical Oncology

Contributors

Role:
Supervisor
Publication date:
2012
Type of award:
DPhil
Level of award:
Doctoral
Language:
English
Keywords:
Subjects:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP